Hemodynamic Dysfunctions in COVID-19 Patients
DOI:
https://doi.org/10.33448/rsd-v10i12.20323Keywords:
Coagulation; Coagulopathy; Coronavirus; COVID-19.Abstract
Coronavirus disease 2019 (COVID-19) is a respiratory viral infection caused by the novel coronavirus (SARS-CoV-2). Thus, it objected to comprehend the pathophysiology of COVID-19, as well as its clinical repercussions on hemodynamic alterations. This is an integrative literature review, such a method is able to select and include experimental and non-experimental studies, qualitative in nature, descriptive and exploratory in character. Initially, it started from the guiding question: "What hemodynamic dysfunctions can the positive COVID-19 patient develop?" The study was conducted by searching the database: PUBMED, using the descriptors: "coagulopathy" and "COVID-19", combined by the Boolean operator AND. As inclusion criteria, the filters of one-year version, full text, clinical trial, meta-analysis, and randomized controlled trial were chosen. Coagulopathy and thromboembolic events are manifestations of COVID-19 and are designated as poor prognostic factors. The respiratory system is the main target of SARS-CoV-2, but other body systems may also be involved. Therefore, symptoms can range from respiratory distress to multiple organ failure. It is concluded that the presence of coagulopathy is a major source of mortality in COVID-19 positive patients. Also, coagulopathy is linked to the severity of the symptomatology of COVID-19, and that in more severe cases relatively increased levels of D-dimer, prothrombin time, and fibrinogen are present. In addition, no significant minimization in platelet levels was observed in severe cases of COVID-19.
References
Al-Ani, F., Chehade, S., Lazo-Langner, A. (2020). Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 192, 152-160. 10.1016/j.thromres.2020.05.039.
Bahrami, M., et al. (2020). Cytokine storm in COVID-19 and parthenolide: preclinical evidence. Phytother Res. 34, 2429–30. 10.1002/ptr.6776.
Bemtgen, X., et al. (2021). Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thromb Thrombolysis. 51(2), 301-307. 10.1007/s11239-020-02217-1.
Brandão, S. C. S. et al. (2020). COVID-19 grave: entenda o papel da imunidade, do endotélio e da coagulação na prática clínica. Jornal Vascular Brasileiro [online]. 19, e20200131. 10.1590/1677-5449.200131.
Chistolini, A., et al. (2020). Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. Br J Haematol. 190(4), e214-e218. 10.1111/bjh.17003.
Connors, J. M. & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood. 135(1), 2033–40. 10.1182/blood.2020006000.
Fox, S. E., et al. (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 8(1), 681–86. 10.1016/S2213-2600(20)30243-5.
Gil, A. C. (2002). Como elaborar projetos de pesquisa. (4a ed.), Atlas, 2002.
Godoy, A. S. (1995). Introdução à pesquisa qualitativa e suas possibilidades. Revista de Administração de Empresas, 35(2), 57-63.
Goshua, G., et al. (2020). Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 7(8), e575-e582. 10.1016/S2352-3026(20)30216-7.
IBA, T., et al. (2020). The unique characteristics of COVID-19 coagulopathy. Crit Care. 18(24), 360-9. 10.1186/s13054-020-03077-0.
Ibañez, C., et al. (2021). High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis. 51(2), 308-312. 10.1007/s11239-020-02226-0.
Kamel, A. M., et al. (2021). Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol. 31(3), e2180. 10.1002/rmv.2180.
Leung, T. Y. M., et al. (2020). Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 9(1), 2190-2199. 10.1080/22221751.2020.1825914.
Libby, P. & Lüscher, T. (2020). COVID-19 is, after all, an endothelial disease. Heart J. 41(1), 3038–3044.
Mcbane, R. D. 2ND, et al. (2020). Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. Mayo Clin Proc. 95(11), 2467-2486. 10.1016/j.mayocp.2020.08.030.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., Shitsuka, R. (2018). Metodologia da pesquisa científica. UFSM. https://repositorio.ufsm.br/bitstream/hand le/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1
Polimeni, A., et al. (2021). Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. Sci Rep. 17(11), 10464-68. 10.1038/s41598-021-89967-x.
Ranucci, M., et al. (2020). The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 18(1), 1747–51. 10.1111/jth.14854.
Tang, N., et al. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 18(1), 844–47. 10.1111/jth.14768.
Thachil, J., et al. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 18(1), 1023–26. 10.1111/jth.14810.
Triviños, A. N. S. (1987). Introdução à pesquisa em ciências sociais: a pesquisa qualitativa em educação. Atlas, p. 100.
Uaprasert, N., et al. (2021). Systemic Coagulopathy in Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 27(1), 076029620987629. 10.1177/1076029620987629.
Xiang, G, et al. (2021). The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis. Medicine (Baltimore). 19(100), e24537. 10.1097/MD.0000000000024537.
Zhang, X., et al. (2020). Coagulopathy in patients with COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 24(12), 24535-24551. 10.18632/aging.104138.
Whittemore, R. & Knafl, K. (2005). The integrative review: update methodology. J Adv Nurs. 52(5), 546-53.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Rubens Barbosa Rezende
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
